AMG 337

Drug Profile

AMG 337

Alternative Names: AMG337

Latest Information Update: 06 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastric cancer; Oesophageal cancer; Solid tumours

Most Recent Events

  • 06 Jul 2017 Chemical structure information added
  • 12 May 2017 NantPharma plans the QUILT-3.036 phase II trial for Solid tumours (Metastatic disease, Late-stage disease) (NCT03147976)
  • 03 May 2017 NantPharma plans the phase II QUILT-3.031 trial for Clear cell sarcoma (In adolescents, In adults, In the elderly, Late-stage disease, Metastatic disease) in USA (NCT03132155)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top